Zenas BioPharma (ZBIO) Capital Expenditures (2024 - 2026)

Zenas BioPharma's Capital Expenditures history runs 3 years deep, the most recent figure standing at $2000.0 for Q1 2026.

• In Q1 2026, Capital Expenditures fell 88.89% year-over-year to $2000.0; the TTM figure through Mar 2026 stood at $2000.0 (down 98.43% YoY), while the FY2025 annual figure was $18000.0, down 86.26% from the prior year.
• Capital Expenditures was $2000.0 for Q1 2026 at Zenas BioPharma, down from $18000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $74000.0 in Q4 2024 to a low of $2000.0 in Q1 2026.
• Historically, Capital Expenditures has averaged $30200.0 across 3 years, with a median of $22000.0 in 2024.
• The sharpest annual moves came in 2025 and 2026: Capital Expenditures decreased 18.18% in 2025, then tumbled 88.89% in 2026.
• A 3-year view of Capital Expenditures shows it stood at $74000.0 in 2024, then plunged by 75.68% to $18000.0 in 2025, then sank by 88.89% to $2000.0 in 2026.
• The last three Capital Expenditures figures came in at $2000.0 (Q1 2026), $18000.0 (Q1 2025), and $74000.0 (Q4 2024), per Business Quant data.